知镜 Cognispect · 医学文献与研究工作台

PTPN6/SHP-1 in autoimmune disease: immune tolerance, regulatory mechanisms, and therapeutic targeting.

Chang RC, Lasalle C, Wang Y, Markovics A, Amber KT, Mansini AP.
Frontiers in immunology · 2026-05-20 · PMID 42245657

文献摘要

PTPN6 encodes SHP-1, a central regulator of immune tolerance and a critical signaling brake across innate and adaptive immunity in autoimmune disease. Predominantly expressed in hematopoietic cells, SHP-1 restrains receptor-proximal signaling downstream of antigen, cytokine, and pattern-recognition receptors, thereby setting activation thresholds that preserve immune homeostasis and limit autoreactivity. Converging evidence from human genetics, patient-derived immune cells, and animal models indicates that diminished SHP-1 activity promotes persistent autoreactive lymphocyte responses, exaggerated inflammatory signaling, and tissue-specific injury across systemic lupus erythematosus, rheumatoid arthritis, neutrophilic dermatoses, multiple sclerosis, psoriasis, and type 1 diabetes. Beyond its role in disease pathogenesis, SHP-1 has emerged as a therapeutically relevant node, particularly through strategies designed to enhance phosphatase activity and restore immune restraint. However, clinical translation remains constrained by challenges in phosphatase selectivity, context-dependent biology, and tissue-specific delivery. This review integrates current understanding of SHP-1 regulatory mechanisms, disease-specific evidence, and emerging translational opportunities, highlighting PTPN6 /SHP-1 as a candidate target for precision immunomodulation in autoimmune disease.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。